Difference between revisions of "Abiraterone"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
'''Abiraterone''' is an androgen synthesis inhibitor used to treat [[prostate cancer]].<ref name=pmid23887973>{{Cite journal | last1 = Mitsiades | first1 = N. | title = A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. | journal = Cancer Res | volume = 73 | issue = 15 | pages = 4599-605 | month = Aug | year = 2013 | doi = 10.1158/0008-5472.CAN-12-4414 | PMID = 23887973 }}</ref> | '''Abiraterone''' is an androgen synthesis inhibitor used to treat [[prostate cancer]].<ref name=pmid23887973>{{Cite journal | last1 = Mitsiades | first1 = N. | title = A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. | journal = Cancer Res | volume = 73 | issue = 15 | pages = 4599-605 | month = Aug | year = 2013 | doi = 10.1158/0008-5472.CAN-12-4414 | PMID = 23887973 }}</ref> | ||
==See also== | |||
*[[Prostate cancer]]. | |||
==References== | ==References== | ||
Revision as of 03:00, 20 May 2016
Abiraterone is an androgen synthesis inhibitor used to treat prostate cancer.[1]
See also
References
- ↑ Mitsiades, N. (Aug 2013). "A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.". Cancer Res 73 (15): 4599-605. doi:10.1158/0008-5472.CAN-12-4414. PMID 23887973.